Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

VOGX

Strong Sell

Vogenx, Inc. · Healthcare · United States · $504M

5
StockRank
Get insider-trade alerts
Q
22
V
25
M
25
P/E (TTM)
—
ROE
—
D/E
—
Dividend %
—
Dir. Trades · 180d
None →
Buybacks · 180d
None →

COMPANY DESCRIPTION

Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857.

FINANCIAL SUMMARY (USD)

Year20242025TTM
Revenue00—
EPS-0.29-0.19-0.11
Shares13.9M13.9M14.9M
Debt—0.8M0.8M
Equity0.5M-0.9M—
Op CF-2.3M-1.1M-1.1M
Inv CF———
Fin CF00.8M—
Loading 1Y...
PRICE (1Y)+161.2%
13.0018.2423.4828.7233.96Aug 12Aug 20Aug 28

Close
$33.96

SCORE BREAKDOWN

Quality
22
ROIC (ROA)
-212.2%*2.5
ROE
—N/A
GP/Assets
—N/A
Op. Margin
0.0%40.1
FCF/Assets
—N/A
Piotroski
325.3
Int. Cover
—N/A
D/E Ratio
—N/A
Current Ratio
0.39x1.8
Value
25
P/E (TTM)
—N/A
EV/EBITDA
—N/A
P/FCF
—N/A
P/B
-123.6x25.0
P/S
—N/A
Div Yield
—N/A
Momentum
25
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$504M
P/E (Forward)
—
Gross Margin
—

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VOGX are excluded.

TickerCompanyMkt CapStockRankSignal
VOGXVogenx, Inc.(you)$504M5Strong Sell
CMPXCompass Therapeutics, Inc.$432M5Strong Sell
CAPRCapricor Therapeutics, Inc.$558M3Strong Sell
SCTXScribe Therapeutics Inc.$460M2Strong Sell
EVMNEvommune, Inc.$480M9Strong Sell
OCGNOcugen, Inc.$448M1Strong Sell
SPRYARS Pharmaceuticals, Inc.$586M8Strong Sell
BLSMBlossomHill Therapeutics, Inc.$569M9Strong Sell
PROKProKidney Corp.$731M4Strong Sell
KYTXKyverna Therapeutics, Inc.$518M12Strong Sell

Peer medians: ROE -25.8% · P/E 29.5x · Gross margin 58.7%

Vogenx, Inc. (VOGX): Stock Score Summary

Vogenx, Inc. (VOGX) has a MoatMap StockRank of 5/100 based on Quality (22/100), Value (25/100), and Momentum (25/100) factor scores. The current signal is STRONG SELL.

Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857.

Key Financial Metrics

Price$33.96
Market Cap$504M
Price/Book-123.61
Operating Margin0.0%

Vogenx, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Vogenx, Inc.’s (VOGX) StockRank?
MoatMap’s StockRank for Vogenx, Inc. (VOGX) is 5/100, with a Strong Sell signal. It is a composite of Quality (22), Value (25), and Momentum (25) factor ranks across MoatMap’s 20,000+ stock universe.
Does Vogenx, Inc. have an economic moat?
Vogenx, Inc. (VOGX) has a Quality factor score of 22/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Vogenx, Inc. a buy, hold, or sell?
MoatMap’s current signal for Vogenx, Inc. (VOGX) is Strong Sell, based on a StockRank of 5/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Vogenx, Inc. in?
Vogenx, Inc. (VOGX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksVOGX deep dive reportAI ChampionsHow we score stocksSense-check another stock